Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
スポンサーリンク
概要
- 論文の詳細を見る
Mutations in bone morphogenetic protein (BMP) receptor IA (BMPRlA) are responsible for a subset of cases of juvenile polyposis(JF) syndrome that develops hamartomatous tumors in the gastrointestinal tract. Mouse genetic studies have shown thatsuppression of BMP signaling in the intestines causes JP-type hamartoma development. Here, we generated K19-Nog transgenic miceexpressing noggin, a BMP antagonist, in gastric epithelium. However, inhibition of BMP signaling did not cause gastric phenotypes.We thus crossed K19-Nog with K19-C2mE mice that expressed Ptgs2 and Ptges in the stomach to generate compound transgenic mice. Expression of Ptgs2 and Ptges results in prostaglandin E2 (PGE2) biosynthesis, and both enzymes are induced in most human gastrointestinal tumors. Importantly, K19-Nog/ C2mE compound mice developed gastric hamartomas that were morphologicallysimilar to those found in JP with mucin-containing dilated cysts and inflammatory infiltration. Notably, treatment of K19-Nog/C2mE mice with a cyclo-oxygenase-2 inhibitor, celecoxib, significantly reduced tumor size with suppression of angiogenesis, suggesting that induction of the FGE2 pathway together with inhibition of BMP signaling is required for gastric hamartoma development.Moreover, microarray analyses revealed that canonical Wnt signaling target genes were not induced in K19-Nog/ C2mE hamartomas, indicating that BMP inhibition and PGE2 induction lead to gastric hamartoma development indepen- dent of the Wnt/ß-catenin pathway. These results, taken together, suggest that the FGE2 pathway is an effective preventive target against BMP-suppressed gastric hamartomas, as well as for Wnt/ß-catenin-activated adenocarcinomas. ©2009 American Association for Cancer Research.
- 2009-04-01
論文 | ランダム
- 薬物療法--有用性と副作用対策を中心に 分子標的治療薬 新規開発薬 Jak阻害薬 (関節リウマチ(第2版)--寛解を目指す治療の新時代) -- (関節リウマチの治療)
- 薬物療法--有用性と副作用対策を中心に 分子標的治療薬 新規開発薬 リツキシマブ(抗CD20抗体) (関節リウマチ(第2版)--寛解を目指す治療の新時代) -- (関節リウマチの治療)
- 生物学的製剤大規模試験のエビデンス--我が国における試験を中心に BeStスタディ (関節リウマチ(第2版)--寛解を目指す治療の新時代) -- (関節リウマチの治療)
- 関節リウマチに対する大量血球処理白血球除去療法(アフェレシス療法における新しいmodality)
- 関節リウマチに対する生物学的製剤の臨床効果と作用機序